痴呆
生物标志物
神经心理学
药物开发
认知
临床试验
心理学
医学
疾病
认知功能衰退
临床心理学
药品
精神科
病理
生物化学
化学
作者
María K Jónsdóttir,John Harrison,Kristín I Hannesdóttir
摘要
Clinical assessment remains the gold standard for diagnosing dementia, monitoring progression, and conducting clinical research. Biomarkers hold promise for targeted therapeutic approaches, selection of participants in clinical trials, and direct physiological efficacy readouts. However, the anchoring of biomarker research to clinical symptomatology is often based on short and insensitive cognitive screening. This gives the impression that cognitive symptoms occur relatively late and that their progression in the early stages of the disease is slow. A thorough cognitive assessment is a powerful tool and has a key role in the accurate and early diagnosis of dementia. It is very different from the cognitive testing usually seen in biomarker research and drug development. Yet the distinction between these approaches is unclear to many. This paper highlights the misconceptions around cognitive research in dementia and suggests a way forward to facilitate biomarker and drug development through the improved utility of cognitive assessment tools.
科研通智能强力驱动
Strongly Powered by AbleSci AI